Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
That is some very good news. I guess that explains why we were up 14% on Friday for no reason.
Any reason we are up 14%? Maybe Phantom should write a summary every week.
Thank You and Happy Holidays to You and All.
To be honest, I can not say that I am shocked by another delay.
It just seems to be, it is what it is.
Hope so, buy we probably have to wait on some trial news data that Phantom said we should/may get before the end of the year.
Not good news for CAR-T companies if they do step in.
Thank You
Thank You
Who won the Thanksgiving Contest and with what stock? Thanks
I hope we can get to the point where we can do the very best type of advertising possible for free.
Great trial data presented as ASH and ASCO.
Phantom, I will start with a Thank You.
"We want to believe that Marker is the crème de la crème of cell therapy companies but the reality is they are just one of many and are still very small. They need to reach as many eyes as possible however possible and if they are paying for some of these appearances I would assume the cost to be negligible. As we all know the data will be the ultimate decider here. I was fortunate enough to be able to speak with Vera earlier this week and he seems very optimistic about the lymphoma data. I expect we have full data by the end of next year and if it can just mirror the BCM data I am confident none of these videos and "promo" pieces will be a concern to you any more."
OK, Thank You.
The reason all of these TPIV connections bothered me so much is because TPIV was dealing with lowlife Stratton Oakmont pumpers then (and management should have known better), and I just felt like, if we want to be a respectable biotech company, then act like it and do not associate yourself with pumps firms.
The reason I said that Caro was working for 2 years was from the quote:
"Not saying that you would f**k me or my family but to cut my portion of Marker in my opinion is wrong as I 100% brought this back to the table a year later."
So I read that, whatever Caro was doing, there were discussions concerning it a year previous to it actually starting.
I have no intention of ever selling unless we go over $50 (assuming we don't have another reverse split) as my stubborn mentality would rather lose it all then concede.
Thank You for your continued reasonable imput as you tend to calm me down a bit over these many years when I get worked up about something.
John Bonfiglio, various high level roles at Allergan, Peregrine Pharmaceuticals, Cypress Bioscience, Immune Response, Argos Therapeutics, GT Biopharma, Genprex, and our TapImmune.
Peregrine PPHM, was my biggest "realized/sold" loss. It will move down to #2 if MRKR doesn't make good.
To understand this post, another part of the Caro/TPIV/MRKR lawsuit concerned a company called Jupiter Wellness.
Another person in common to both TPIV and Jupiter Wellness was Glynn Wilson.
Glynn Wilson, former long time TapImmune CEO + Chairman, now MRKR.
Glynn Wilson was also CEO, Chairman of the Board and Chief Science Officer of CBD Brands (developing cannabinoid CBD products for skin, hair, sexual wellness) (Ha Ha).
CBD Brands then became Jupiter Wellness (with our TPIV/MRKR reverse merger guys Brian John, Richard Miller, and Robert Koch).
As another side note, Brian John also started and was CEO of Jupiter Wellness Acquisition Corp (a SPAC - special purpose acquisition company) that merged with Chijet Motor Company (Chinese EV company) (nasdaq CJET).
Back to CBD brands Jupiter Wellness (went nowhere) and changed name to Safety Shot (nasdaq SHOT) after they bought a MAGIC drink from GBB Drink Lab for ONLY 7.5 million dollars that claims to lower your BAC (blood alcohol content) by 50% in a half an hour (no proof, just hype, Ha Ha).
Safety Shot has now Brian John CEO, Glynn Wilson Board Chairman and Chief Science Officer.
As expected, our 4 friends Brian John, Richard Miller, Robert Koch, Glynn Wilson have been involved with dozens of companies that went nowhere and killed investors.
A report just released on Safety Shot from Capybara Research.
"Safety Shot Exposed - Unraveling the Fraud Behind the Drink and Its Dubious Origins"
https://www.capybararesearch.com/post/safety-shot-exposed-shot
Apparently the clowns mentioned in the previous post (should read that post first) worked on/did the TPIV/MRKR reverse merger. It looks like in addition to any cash for services, they got 130,000 shares of MRKR.
Some fun read quotes from the lawsuit (from their emails):
"Koch responded that he did not believe he had done poorly, and mentioned that Caro Partners continued to hold what he believed was $300,000 worth of Marker shares. John called this "Koch math" and claimed we each have 65,000 shares is 240 grand not 300. Told Mag they think I'm gonna spend some time in jail. somethings got a change in the split for me taking the risk when we're done."
"Not saying that you would f**k me or my family but to cut my portion of Marker in my opinion is wrong as I 100% brought this back to the table a year later."
"I feel like for the last year you've done nothing but try and live off the marker haven't signed a deal."
"I had 65k shares left at the end of Dec and only saw 150k since the 10th of December from mrkr."
"Koch asked: "Out of the mrkr money ?". John wrote: "That's the only money we got in a world where the hell else is it going to go I sure as f**k ain't going to get thrown in jail because we didn't raise the f*****g money we were supposed to."
OK, well that's some interesting reading for sure, and these were the scam clowns who worked on the TPIV/MRKR reverse merger for sounds like about 2 years before it actually happened.
Sure am glad they were on OUR side. Boy has my confidence been building for the last 2 days. I went from "I will continue to give Juan the benefit of the doubt until he just really screws something up" to "is this just a pump and dump scam for continued big salaries plus benefits".
Anyway, as I have now typed several posts going back to 11-21, any comments or opinions on them?
P.S. I canceled my open buy order for $2.22.
Hello all, hope the turkey was good. Speaking of turkeys .... you may just want to read this.
I found another interesting and somewhat discouraging and disheartening tidbit of information from a 2021 lawsuit.
The info can be found here: https://casetext.com/case/caro-capital-llc-v-koch
Long story short, for anybody who have seen the movie "The Wolf of Wallstreet", Stratton Oakmont was the biggest scam pump and dump penny stock brokerage out there.
Three scam clowns who worked there in the 1990's were Brian John, Richard Miller, and Robert Koch.
Later on John and Miller had a scam pump and dump company called Caro Capital and Koch had a scam pump and dump "consulting services" company called Caro Partners (there were no partners, one man show, just Koch).
Now, Koch has a criminal history. He pleaded guilty to several counts of felony securities fraud and was sentenced in June 2012. Because of his convictions, Koch is not permitted to take on certain roles in the securities industry.
From 2015 to 2019, Miller and John (Caro Capital) sporadically hired Koch as an independent contractor to work on discrete projects.
Amongst other issues, the 2021 lawsuit concerned "$370,000 for services rendered to TapImmune, Inc" (now Marker Therapeutics MRKR).
If Koch (and Bedford) were owed $370,000 for subcontract "consulting" work from done for Caro Capital, what was the total bill amount from Caro Capital to TapImmune, 1 million?
So, for Many Years, several times, we have had TPIV/MRKR paying investor money to Scam Pump and Dump, Hype/Promote firms.
Scam Pump and Dump firms paid.
11-23 Empowered Patient Podcast.
11-23 HealthPro Radio.
8-23 Intelligence360 News.
6-23 Proactive.
5-19 RedChip.
Now we find Caro and Koch.
Why exactly? For what purpose? To achieve what outcome?
I sure would love to hear some feedback and/or opinions.
HAPPY THANKSGIVING TO ALL .... go mrkr
Dear Dr. Vera,
I know that you are a very busy man and I apologize for taking your time and I will be as brief as possible.
I've been with MRKR going back to early TPIV. When we became MRKR I put in another 100K and have continued to add as the share price has gone down, now over 225K.
To the point.
Video just done with EmpoweredPatientPodcast. EmpoweredPatientPodcast hosts "SPONSORED STORIES" (from their website).
Video done a week ago on HealthProRadio. Health Professional Radio is an online radio "PROMOTING" company (from their website).
Video done August 2023 done with Intelligence360 News. Same, promotion firm.
Video done June 2023 done with Proactive. Same, promotion firm.
All the way back to video done May 2019 with RedChip. Same, promotion firm.
The purpose of these paid "promotion" firms is normally to promote/pump the stock to gain investors to raise the share price. As most Doctors are too busy to see them, they do little to make Doctors aware of Marker or their Multi-TAA therapy and it's advantages over CAR-T therapy.
My question is why are we paying these promotion/pump firms instead of trying to raise awareness with Doctors to try to increase FDA trial enrollments to both get more trial data quicker and to try to help more patients?
As most Doctors know about CAR-T but not Multi-TAA, if we want to raise awareness with Doctors about Marker and their Multi-TAA therapy and it's advantages over CAR-T therapy, have you considered spending some money to advertise with some large size ads in the most prestigious medical journals like JAMA (Journal of the American Medical Association), The New England Journal of Medicine, Journal of Clinical Oncology?
I do not believe that these promote/pump firm videos are a good look for us.
Thank you for your consideration, (name deleted for this post)
P.S. I am writing my second email ever to Dr. Vera concerning this promotion firms issue. Also about medical journal advertising. I will let you know any answer if I get one.
Phantom or Jobynimble or ANYBODY. OK, NOW I am getting pissed off. Please read entire post.
Video just done with EmpoweredPatientPodcast.
EmpoweredPatientPodcast hosts "SPONSORED STORIES" (from their website) and is owned by Turtleback Interactive LLC - turtlebackinteractive.com
WHY ARE WE PAYING THESE F...ING HYPE FIRMS ?
Doctors don't have time to listen to this crap and learn about MRKR Multi-TAA, the purpose is to gain investors.
Video done a week ago on HealthProRadio. healthprofessionalradio.com.au
Health Professional Radio is an online radio PROMOTING company (from their website).
WHY ARE WE PAYING THESE F...ING HYPE FIRMS ?
Doctors don't have time to listen to this crap and learn about MRKR Multi-TAA, the purpose is to gain investors.
Video done August 2023 done with Intelligence360 News. Hype firm.
WHY ARE WE PAYING THESE F...ING HYPE FIRMS ?
Doctors don't have time to listen to this crap and learn about MRKR Multi-TAA, the purpose is to gain investors.
Video done June 2023 done with Proactive. ANOTHER Hype Firm
Goes back to video done May 2019 with RedChip. ANOTHER Hype firm.
WHAT THE F..K IS WITH THIS PAYING MONEY TO BU.LSH.T HYPE FIRMS?
If you are trying to waste money trying to gain investors with crap videos nobody F...ING watches, then KEEP THIS CRAP UP.
If you want to educate Doctors about Multi-TAA and try to increase enrollments, then for the 3rd F...ING time.
MRKR should spend some money and advertise with some full page ads in the most prestigious medical journals like JAMA (Journal of the American Medical Association), The New England Journal of Medicine, Journal of Clinical Oncology in order to raise awareness of their Multi-TAA therapy, so that they can treat more patients and have quicker enrollment progress which hopefully would lead to a larger amount of postive result data?
SERIOUSLY ... WHAT THE F..K
ANY OPINIONS???????????????????????????????????????
Thank You Again. I don't know how you find this stuff before anyone else.
I DO have some questions for anyone who would like to answer them.
Concerning these recent Juan interviews ... is MRKR PAYING for these like they have done in the past with 2 other HYPE firms?
I will look into the recent interview companies after I post this.
Howdy PL, Yes I thought it was strange that Lurieu leaving on Nov. 17 but yet the contract ends Jan. 16.
The only thing I could think of was: MRKR didn't like Lurier as CFO but couldn't just end the whole contract without some big penalty, so they agreed to just ditch the CFO part (to Juan) and let Danforth continue with the rest of the stuff like HR and then end the contract as a whole in Jan..
I do not like strange unexplained stuff, I will continue to give Juan the benefit of the doubt until he just really screws something up and turns into Peter Hoang, but I hope that does not happen.
THANKS
any comment on my last post #34308?
4 1/2 % - WOW just amazing - what skill and foresight.
Other Charts
look at the long term chart of VRTX.
Nov. 2000 at $94.
May 2004 at $8.
Boy that chart really sucked.
Nov 2023 at $356.
90 Billion market cap.
or SGEN
May 2004 at $11
July 2006 at $4
terrible performance
Nov 2023 Pfizer buying for 43 Billion at $229 per share.
or ALNY
August 2008 at $35
Nov 2011 at $6
horrible performance
Jan 2023 at $225
biotechs take time, but if you pick the right ones, they pay off very well.
And Honestly, it's a lot more fun and a bit more skillful than buying a USA T bill.
Or buying GE for a dividend when share price went from $370 in 2000 to a current price of $120.
Or S+P 500 index fund:
If you invested $100 in the S&P 500 at the beginning of 2000, you would have about $488.05 at the end of 2023, assuming you reinvested all dividends. This is a return on investment of 388.05%, or 6.93% per year.
Wow 7% a year. What enormously skillful returns.
But don't forget about inflation:
The dollar had an average inflation rate of 2.44% per year between 2000 and 2022.
So the REAL return per year on S+P 500 index since 2000 is about 4 1/2 %.
I'm happy retiring at 54 with my IT stocks and biotech stocks.
Not sure I'd be bragging about a 4 1/2 % yearly return over the last 23 years.
Howdy bar1080, Just reading all the posts in order and saw your chart (I think it's the same one from your Nov. 4 post) but I have a question concerning the "Bearish" emoji.
For the chart, it doesn't bother me, it looks like hundreds of other biotech charts. People bid it way on the positive sounding initial news, then it slowly sells off as people realize it takes many years to get through FDA trials, and then if it get approval it takes off to 10 times or more the previous high.
But my question is WHY the bearish.
Is it just all biotechs you're bearish on?
If so, I won't repeat all the bios that went from being worth next to nothing to many billions.
Or is there something specific about MRKR that you are bearish about.
Is it the technology or the financials or the management?
Seriously, if there is a specific reason or reasons, as an investor I would like to be informed. I try to take in and process as much information as I can.
I'm not much on snap judgements or just saying something without a reason for saying it.
I layed out my reasons for being bullish in my first reply which I'm guessing you read.
If you can, please point out the flaws of Multi-TAA as you see them.
Thanks.
I remember posting on this board and asking about this "Danforth Consulting Agreement", what were the terms? the pay structure? where can I read the contract?
I think Phantom said I would never get to read the contract, it was private.
He was again correct.
I never liked the "smell" of it. Glad Danforth is history. I trust Juan a heck of a lot more. Time to move on.
In case you missed it, I am going to copy and paste.
P.S. Just like our buddy LC used to drive me crazy until I just got tired of it and blocked him, don't let people bother you.
I have repeated my whole life a concept of cognitive psychology:
"People don't bother you, you let people bother you."
That is something I have to constantly remind myself of.
LC reminded me many times about that.
I just type my honest replies.
make that up 36% on day one. $1.60 to $4.34 in last 2 weeks.
took a SHOT (pun intended), wish MRKR would start doing that as I have about a zillion times more in MRKR, but I know, it will take time. Hoping for great trial data in 2024 and beyond.
For readers. I do NOT suggest taking a shot on SHOT, as I said, I think it's a scam. With momentum and "the trend is your friend", it could keep going to $20+ or could could dive back to $1.
I really have no idea.
Oops, I just posted the same thing. I was typing my reply to bar1080 and I didn't see that you already posted the 8-K.
Thank You
P.S. Just like our buddy LC used to drive me crazy until I just got tired of it and blocked him, don't let people bother you.
I have repeated my whole life a concept of cognitive psychology:
"People don't bother you, you let people bother you."
That is something I have to constantly remind myself of.
I just type my honest replies.
8-K filed.
On November 17, 2023, Marker Therapeutics, Inc. (the “Company”) delivered a notice of termination (the “Notice”) to Danforth Advisors, LLC (“Danforth”) terminating the consulting agreement (the “Danforth Consulting Agreement”) by and between the Company and Danforth, dated June 6, 2023, pursuant to which, among other things, Eliot M. Lurier was appointed as the Company’s Interim Chief Financial Officer. Pursuant to the Notice, the Danforth Consulting Agreement will terminate on January 16, 2024.
On November 17, 2023, Mr. Lurier ceased serving as the Company’s Interim Chief Financial Officer and Principal Financial and Accounting Officer and Juan Vera, the Company’s President and Chief Executive Officer, was appointed as the Company’s Principal Financial and Accounting Officer. The biographical data and related-person transactions disclosures for Dr. Vera, as set forth in the Company’s definitive proxy statement on Schedule 14A filed by the Company with the U.S. Securities and Exchange Commission on April 28, 2023, are incorporated herein by reference.
Hello bar1080, That's an easy answer. The contest is for a one week period, Nov 20 to Nov 24 and I don't expect MRKR to do anything in the next week. I used a stock that I honestly think is a scam (SHOT) but knowing how penny stock players think and how it has been moving for the last 2 weeks, I figured it was the best "one week" bet I could make.
But back to MRKR, Let's leave aside bio technologies like RNAI and MRNA and CRISPR (which are all genetically engineered and have all had severe side effect problems including patient deaths) and just compare CAR-T to MRKR's Mulit-TAA, it is hard not to see the advantage of Multi-TAA (Tumor Associated Antigens).
CAR-T (chimeric antigen receptor -T cell therapy) is ALSO genetically engineered.
Has had many problems with Cytokine release syndrome (BAD).
Has killed patients (WORSE than BAD).
Only targets one antigen.
Costs much more and takes much longer to produce.
Multi-TAA is NOT genetically engineered.
Has had NO problems with Cytokine release syndrome or patient deaths.
Targets Multi antigens for each specific cancer indication.
Induces Epitope spreading (the body creates other antigens to target the cancer naturally besides those that were introduced).
Costs much less and much quicker to produce.
Has had success so far in Phase 1 and Phase 2 trials.
MRKR, IF IF IF everything goes according to plan, will pay off big in the second half of 2024 and in 2025.
By the summer of 2024, we should have a decent amount of trial data on AML and Lymphoma.
Also working on Panceatic (a ways off and a much tougher cancer to crack).
As we discussed on the other IHUB board, when you buy them when they are small and hold them, an up 10,000% is not out of the question.
VRTX, SGEN,EXEL,ALNY, ARWR, PCYC (bought by AbbVie), all went from small to many Billions in market cap for me.
But as you never really know when good news will come out, you just have to buy and hold, but for MRKR, it should be an end of 2024/2025 big payoff.
Another much closer payoff is IOVA who is working on TIL technology. TIL - tumor infiltrating lymphocyte therapy.
We are waiting for final data and FDA approval in Feb. 2024.
BIG payoff IF IF IF. Gilead might just buy them out.
Speaking of Gilead, MRKR has a sister company, Allovir, ALVR (same founders) that Gilead own a giant chunk of.
I know that you are a bond and dividend guy, but check all 3 of them out, you may want to take a small flyer position on 1 or 2 or all 3 of them.
Good Luck.
To be honest, I did NOT use MRKR for the IHUB ORIONS Money Stocks Thanksgiving Stock Picking Contest.
Contest entries here: https://investorshub.advfn.com/boards/read_msg.aspx?message_id=173260681
Wish there was a big money cash prize as I am up about 20% in the first hour of day #1.
Orion's Contest Turkey 2023 Pick $SHOT
What is with the after hours selling every day taking from green to red?
Just listened to Dr. Vera. "MRKR has treated over 200 patients" - I hear, ONLY 200 patients - so I am going to circle back to something that, in the big picture, would NOT cost that much money and MAY be a big help in treating more patients FASTER.
MRKR should spend some money and advertise with some full page ads in the most prestigious medical journals like JAMA (Journal of the American Medical Association), The New England Journal of Medicine, Journal of Clinical Oncology in order to raise awareness of their Multi-TAA therapy, so that they can treat more patients and have quicker enrollment progress which hopefully would lead to a larger amount of postive result data?
Every Doctor has CAR-T on the brain and never heard of Multi-TAA.
Ad with giants letters.
BETTER - FASTER and CHEAPER THAN CAR-T
NOT Genetically Engineered
NO Cytokine Release Syndrome
VERY POSITIVE Trial Results
ENROLL and SAVE Your Patients
THANK YOU
They "CLAIM" "newly found ‘kill switch’ (CD95 Fas) triggers death of cancer cells", BUT NOT so newly found as there are articles going back a decade.
https://www.foxnews.com/health/potential-cancer-breakthrough-newly-found-kill-switch-triggers-death-cancer-cells-one-two-punch
the good part: "CD95 receptors — also referred to as Fas — have gained the nickname "death receptors" because they send a signal that causes cancer cells to "self-destruct"".
the BAD part article CLEARLY states: "Despite many breakthroughs in the cancer immunotherapeutic field, targeting Fas remains neglected, primarily due to fear of retaliation against immune-system T-cells,"
From this 2015 article: https://www.nature.com/articles/cdd20153
The "fear of retaliation against immune-system T-cells" (from above) is explained "The tumor strikes back,
It has been demonstrated a number of times that expression of CD95L by apoptosis-resistant tumor cells enables a powerful ‘counterattack’ against antitumor immune effector cells, such as cytotoxic killer cells, many of which are themselves sensitive to CD95L-mediated apoptosis".
And also: "However, given the fact that almost all established cancers express CD95, and the fact that most cancer cells are resistant to apoptosis induction, we would suggest that stimulating CD95 on cancer cells may not be an effective approach to killing cancer cells".
SO, in conclusion: LET'S GO MRKR AND MULTI-TAA.
Under Program Updates and Expected Milestones: it would have been nice to hear even a single word that was new and not just be told rehashed things we have heard before a dozen times already.
Yes, STILL waiting for that all important "Strategic Review" (said at this point with just a wee bit of sarcasm).
Thank You, It seemed both good and bad, the three-day manufacturing time and CR's seemed good and the Cytokine release syndrome and Neurotoxicity, although not fatal and managed seemed bad. Let's hope we get our data soon (good data).
OK, I admit, I'm confused. All talking about huCART19-IL18. Opinions anybody?
From Nov 2022: https://ashpublications.org/blood/article/140/Supplement%201/4612/491850/Interleukin-18-Secreting-Autologous-Anti-CD19-CAR
Out of 8 patients infused "Cytokine release syndrome (CRS) occurred in 4 (50%) pts: Grade (G)1 in 2, G2 in 1, G3 in 1 with median onset at 7.5 days (2-8) and median duration of 5.5 days (5-11); 2 pts required anti-cytokine therapy. Neurotoxicity occurred in 2 (25%) pts: 1 on day 20 lasting for 2 days (G1) and 1 on day 8 for 6 days (G2). Other non-hematologic G3 or higher adverse events at least possibly related to huCART19-IL18 included infections in 2 (25%), hypotension in 2 (25%), and AST elevation in 1 (12.5%) in the setting of CRS. There have been no study-related deaths."
"Conclusions: In this first-in-human study, huCART19-IL18 shows a manageable toxicity profile and encouraging early efficacy across all dose levels in heavily pretreated pts with CD19+ NHL including those who did not respond to prior 2nd generation CAR T-cell products. Enrollment continues at DL3."
From Dec 2022: https://www.pennmedicine.org/news/news-releases/2022/december/advance-in-re-treatment-with-car-t-therapy
"Among the first seven patients who received huCART19-IL18 – including those who previously did not respond to or relapsed following treatment with commercial CAR T cell therapies – all responded to the therapy (four patients had a complete response and three patients had a partial response). None of the four patients whose cancers completely responded to treatment at month three have seen their disease return, and all patients are alive at a median follow-up of eight months."
"Notably, with a three-day manufacturing time, huCART19-IL18 can be ready to administer more quickly than CAR T products with the typical manufacturing time of nine to 14 days, which is especially important for patients with aggressive, fast-growing disease."
From July 2023: https://www.onclive.com/view/hucart19-il8-proves-safe-and-elicits-durable-responses-in-car-t-pretreated-r-r-lymphoma
"huCART19-IL18 elicited an objective response rate of 82% (95% CI, 53%-97%) in this population (n = 11), which included a complete response rate of 55% and a partial response rate of 27%."
Is any of the above anything to be concerned about in relation to MRKR Multi-TAA?
I don't know if it's apples to apples or apples to oranges??
YEY, back up to $3.33, my last buy in price, and triple my second to last buy in price of $1.11, but having said that, my cost average is still in the low teens, BOOO. Still got that $2.22 buy price waiting to lower my cost average even more, if it happens.